Inaxaplin Reduces Proteinuria in Additional APOL1 Kidney Disease Populations

Company Vertex Pharmaceuticals Event Type Clinical Trial Data Readout Modality Small Molecule Asset Inaxaplin Target APOL1 Disease Area APOL1-Mediated Kidney Disease Summary Vertex reported Phase 2b AMPLIFIED data in 41 people with APOL1 mediated kidney disease. Inaxaplin 45 mg once daily on top of standard…